MARKET

ZIOP

ZIOP

ZIOPHARM Oncolgy
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.650
+0.130
+5.16%
After Hours: 2.640 -0.01 -0.38% 16:52 04/08 EDT
OPEN
2.590
PREV CLOSE
2.520
HIGH
2.700
LOW
2.520
VOLUME
1.23M
TURNOVER
--
52 WEEK HIGH
7.25
52 WEEK LOW
1.795
MARKET CAP
564.45M
P/E (TTM)
-3.8080
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ZIOP stock price target is 5.92 with a high estimate of 7.50 and a low estimate of 3.000.

EPS

ZIOP News

More
  • Ziopharm- Catalysts in T-Cell Therapy
  • MoneyShow · 2d ago
  • Benzinga's Top Upgrades, Downgrades For March 4, 2020
  • Benzinga · 03/04 15:08
  • Cantor Fitzgerald Initiates Coverage On ZIOPHARM Oncology with Overweight Rating, Announces $6 Price Target
  • Benzinga · 03/04 10:10
  • Ziopharm down 6% despite pipeline advancement and cash influx
  • Seeking Alpha - Article · 03/03 16:15

Industry

Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+2.82%

Hot Stocks

Symbol
Price
%Change

About ZIOP

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
More

Webull offers kinds of ZIOPHARM Oncology Inc. stock information, including NASDAQ:ZIOP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZIOP stock news, and many more online research tools to help you make informed decisions.